University of Maryland, Baltimore: Schizophrenia trials
The registry lists 64 Schizophrenia studies with University of Maryland, Baltimore as lead sponsor. 3 are open to participants now and 31 have results posted.
Phase 1 2Phase 2 10Phase 3 3Phase 4 10No phase 42(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Clinical Trial of an IL-23 Inhibitor for Immune Activation in Clinical Trial of an IL-23 Inhibitor for Immune Activation in People With SchizophreniaNot yet recruitingNCT07615075Phase 4
- White Matter Plasticity in SchizophreniaRecruitingNCT06641297Not applicable
- TMS for Inhibition Enhancement in SchizophreniaRecruitingNCT06155682Not applicable
- TMS Related Biomarker AssessmentsCompletedNCT05660018Not applicableResults posted
- The Effects of Kynurenine Aminotransferase Inhibition in People With SchizophreniaCompletedNCT04013555Phase 1/2Results posted
- Cigarette Smoking in Smokers With and Without SchizophreniaCompletedNCT04001114Not applicableResults posted
- Prebiotic Treatment in People With Schizophrenia - Pilot StudyCompletedNCT03617783Phase 4Results posted
- Circuitry-Guided Smoking Cessation in SchizophreniaCompletedNCT03281629Not applicableResults posted
- TMS Enhancement of Visual Plasticity in SchizophreniaTerminatedNCT03220438Not applicableResults posted
- Minocycline and Tobacco Craving in Smokers With SchizophreniaCompletedNCT02968602Phase 4Results posted
- Biomarker and Safety Study of Clozapine in Patients With Benign Ethnic Neutropenia (BEN)CompletedNCT02404155Not applicableResults posted
- Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal ActivityCompletedNCT02118610Not applicableResults posted
- Nicotinic Enhancement of Cognitive Remediation Training in SchizophreniaCompletedNCT02069392Not applicableResults posted
- Tryptophan MRI in People With Schizophrenia and Healthy ControlsCompletedNCT02067975Phase 2/3Results posted
- MedActive: A Smartphone Intervention to Improve Adherence to Antipsychotic MedicationsCompletedNCT01953237Not applicableResults posted
- Oxytocin and CBSST for People With SchizophreniaCompletedNCT01752712Not applicableResults posted
- Effects of Intranasal Oxytocin on Satiety Signaling in People With SchizophreniaCompletedNCT01614093Phase 4Results posted
- Anti-Inflammatory Treatment of SchizophreniaCompletedNCT01514682Not applicableResults posted
- Adjunctive Minocycline in Clozapine Treated Schizophrenia PatientsCompletedNCT01433055Not applicableResults posted
- Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With SchizophreniaCompletedNCT01338298Not applicableResults posted
- Salsalate for Insulin Resistance in SchizophreniaCompletedNCT01182727Not applicableResults posted
- Effects of Galantamine on CognitionCompletedNCT01100775Phase 2Results posted
- Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in SchizophreniaCompletedNCT01012167Phase 2Results posted
- Oxytocin and Social Cognition in SchizophreniaCompletedNCT00884897Phase 2Results posted
- Biomarker Study of Acamprosate in SchizophreniaCompletedNCT00688324Phase 4Results posted
- Effects of Oxytocin Nasal Spray on Social AffiliationCompletedNCT00663039Phase 2Results posted
- Comparison of Varenicline and Placebo for Smoking Cessation in SchizophreniaCompletedNCT00554840Phase 2Results posted
- The Effects of Rimonabant, on Weight and Metabolic Risk FactorsTerminatedNCT00547118Phase 2Results posted
- Varenicline Adjunctive Treatment in SchizophreniaCompletedNCT00492349Phase 4Results posted
- Rasagiline in the Treatment of Persistent Negative Symptoms of SchizophreniaCompletedNCT00492336Phase 4Results posted
- Clinical Trial of Dipyridamole in SchizophreniaCompletedNCT00349973Not applicableResults posted
- Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine PatientsCompletedNCT00176436Phase 4Results posted
- Efficacy Study of Galantamine for Cognitive Impairments in SchizophreniaCompletedNCT00176423Phase 4Results posted
- Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking ClozapineCompletedNCT00056498Phase 4Results posted
- Ketogenic Diet in People With SchizophreniaTerminatedNCT05968638Not applicable
- Prebiotic Treatment in People With SchizophreniaActive, not recruitingNCT05527210Not applicable
- Luteolin for the Treatment of People With SchizophreniaCompletedNCT05204407Not applicable
- Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset PsychosisWithdrawnNCT03883360Phase 2
- Brain Biomarker on Inflammation ResponseWithdrawnNCT03271814Phase 1
- Confirmatory Efficacy Trial of a Gluten-Free Diet in a Subgroup of Persons With Schizophrenia Who Have High Levels of IgG Anti-Gliadin Antibodies (AGA IG)CompletedNCT03183609Not applicable
- Schizophrenia and the Gut MicrobiomeCompletedNCT02921243
- Neuroendocrine and Immune Response to Stress in SchizophreniaCompletedNCT01975584Not applicable
- Biological Evaluation of Dietary Supplement Liposomal GlutathioneCompletedNCT01967667Not applicable
- Randomized Controlled Trial of a Gluten Free Diet In Patients With Schizophrenia Who Are Gliadin-PositiveCompletedNCT01927276Not applicable
- Tobacco Craving and Triggers in Persons With SchizophreniaCompletedNCT01846065
- Long Acting Paliperidone in Dually Diagnosed People With Schizophrenia: An Open-label Pilot StudyWithdrawnNCT01584466Not applicable
- Intracellular Tight Junction Permeability in Schizophrenia: Focus on ZonulinCompletedNCT01558570
- Gluten Free Diet in People With Schizophrenia: A Pilot StudyCompletedNCT01558557Not applicable
- Brain Circuits in Schizophrenia and SmokingCompletedNCT01425684
- Neural Oscillations as Genetic and Functional Biomarkers in Normal and Disease StatesCompletedNCT01425671
- Brain Blood Flow Changes Elicited by Oxytocin in Volunteers With and Without SchizophreniaWithdrawnNCT01123317Not applicable
- Screening Protocol for Research ParticipantsCompletedNCT01010620
- Effects of Smoking Cues on Tobacco Craving Responses and the Reinforcing Efficacy of Cigarettes in Smokers With and Without SchizophreniaCompletedNCT00770237Not applicable
- Knowledge and Perception of Smoking Risks/ConsequencesCompletedNCT00686101
- Bipolar and Schizophrenia Consortium for Parsing Intermediate PhenotypesCompletedNCT00666432
- Familial Schizophrenia and Spectrum Personality DisordersCompletedNCT00666146
- A Self-Management Program for Adults With Both Schizophrenia and a Co-occurring Medical ConditionCompletedNCT00525304Not applicable
- Behavioral Treatment of Drug Abuse in Severe and Persistent Mental Illness (SPMI) PatientsCompletedNCT00295139Not applicable
- Cognitive Remediation for SchizophreniaCompletedNCT00295048Not applicable
- Alcohol Use Disorders in SchizophreniaCompletedNCT00280813Not applicable
- Adjunctive Treatment for Decreasing Symptoms of SchizophreniaCompletedNCT00222235Phase 2/3
- An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit SymptomsCompletedNCT00161044Not applicable
- Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of SchizophreniaCompletedNCT00161031Not applicable
- New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant SchizophreniaCompletedNCT00161018Phase 3